17-OH-Progesterone

Newborn screening programs and adrenal function assessments rely on 17-OH-Progesterone (17-OHP) as a critical biomarker, particularly for its role in evaluating congenital adrenal hyperplasia (CAH) across diverse patient populations. UTAK’s customizable quality control materials feature 17-OHP within our endocrinology panel, with multiple matrix options and concentration levels designed to support both immunoassay and LC-MS/MS testing platforms. Laboratories requiring standalone controls or comprehensive steroid hormone panels that include cortisol, androstenedione, and progesterone can work with our team to develop tailored formulations aligned with specific quality assurance and regulatory compliance needs.